Sponsors Will Need New Databases And Metrics To Determine Success Of Opioids REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA sees REMS assessment as a collaborative effort and already has initiatives with other federal agencies to find ways to monitor indicators of effectiveness.